Table 54.5Studies estimating the association between KSHV infection and AIDS-related Kaposi’s sarcomaa

Reference KSHV antigen targeted Antibody assay format Association between KSHV and AIDS-KS, point estimate (95% CI)b
Case-control studies
Miller et al., 1996 p40 immunoblot 13.4 (4.5–42)
Miller et al., 1996 lytic cycle IFAd 12.2 (4.1–38)
Gao et al., 1996a,b LNAc immunoblot 18.9 (5.4–70)
Kedes et al., 1996 LNA IFA 8.5 (3.1–23)
Gao et al., 1996a,b LNA IFA 16.3 (5.3–50)
Simpson et al., 1996 LNA IFA 10.2 (4.2–25)
Simpson et al., 1996 ORF65 EIAe 9.2 (2.7–31)
Lennette et al., 1996 lytic cycle IFA 1.8 (0.53–5.8)
Lennette et al., 1996 LNA IFA 4.2 (2.2–8.0)
Longitudinal studies
Martin et al., 1998 LNA IFA 2.5 (1.7–3.8)
Renwick et al., 1998f ORF65.2 ORF73 EIA 3.3 (1.9–5.8)
Renwick et al., 1998g ORF65.2 ORF73 EIA 5.2 (2.9–9.3)
O’Brien et al., 1999 LNA IFA 3.6 (1.7–9.5)

limited to studies which measure KSHV infection by antibody response and either directly control for number of sexual partners or restrict analyses to HIV-infected homosexual men


odds ratios are reported for case-control studies and hazard ratios for longitudinal studies


latent nuclear antigen


immunofluorescence assay


enzyme immunoassay


hazard ratio shown is for KSHV prevalent infection


hazard ratio shown is for KSHV seroconverters.

From: Chapter 54, The epidemiology of KSHV and its association with malignant disease

Cover of Human Herpesviruses
Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis.
Arvin A, Campadelli-Fiume G, Mocarski E, et al., editors.
Cambridge: Cambridge University Press; 2007.
Copyright © Cambridge University Press 2007.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.